Leap Therapeutics
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
47 Thorndike St Ste B1-1, Cambridge, Mas...Phone Number
(617) 714-0360Website
www.leaptx.comRevenue
$11.4 MillionStock Symbol
LPTXIndustry
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leaps most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.Explore more
SIC Code 87,873NAICS Code 54,541Ticker NASDAQ: LPTXShow moreLeap Therapeutics Org Chart
Compare Similar Companies to Leap Therapeutics
Compare insights from companies similar to Leap Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Leap Therapeutics Tech Stack
A closer look at the technologies used by Leap Therapeutics
See more technologies
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Leap Therapeutics
Sign Up For FreeTo access detailed company insights
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leaps most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoc... Read More
